Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse

H. C. Diener, David William Dodick, P. J. Goadsby, M. E. Bigal, G. Bussone, S. D. Silberstein, N. Mathew, S. Ascher, J. Morein, J. F. Hulihan, D. M. Biondi, S. J. Greenberg

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Chronic migraine has been linked to the excessive use of acute headache medications. Medication overuse (MO) is commonly considered the most significant risk factor for the progression of migraine from an episodic to a chronic condition. Managing MO is a challenge. Discontinuation of the acute medication can result in withdrawal headache, nausea, vomiting and sleep disturbances. This review summarizes the results from two similarly designed, randomized, placebo-controlled, multicentre studies of chronic migraine conducted in the USA and European Union. Both studies demonstrate the efficacy and safety of the migraine preventive medication, topiramate, for the treatment of chronic migraine in patient populations both with and without MO. These studies may have important implications for the future of chronic migraine management, suggesting that detoxification prior to initiating prophylactic therapy may not be required in all patients if MO is present.

Original languageEnglish (US)
Pages (from-to)1021-1027
Number of pages7
JournalCephalalgia
Volume29
Issue number10
DOIs
StatePublished - Oct 2009

Fingerprint

Migraine Disorders
Headache
Therapeutics
European Union
Nausea
Multicenter Studies
Vomiting
Prescription Drug Overuse
topiramate
Sleep
Placebos
Safety
Population

Keywords

  • Chronic migraine
  • Medication overuse
  • Topiramate

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. / Diener, H. C.; Dodick, David William; Goadsby, P. J.; Bigal, M. E.; Bussone, G.; Silberstein, S. D.; Mathew, N.; Ascher, S.; Morein, J.; Hulihan, J. F.; Biondi, D. M.; Greenberg, S. J.

In: Cephalalgia, Vol. 29, No. 10, 10.2009, p. 1021-1027.

Research output: Contribution to journalArticle

Diener, HC, Dodick, DW, Goadsby, PJ, Bigal, ME, Bussone, G, Silberstein, SD, Mathew, N, Ascher, S, Morein, J, Hulihan, JF, Biondi, DM & Greenberg, SJ 2009, 'Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse', Cephalalgia, vol. 29, no. 10, pp. 1021-1027. https://doi.org/10.1111/j.1468-2982.2009.01859.x
Diener, H. C. ; Dodick, David William ; Goadsby, P. J. ; Bigal, M. E. ; Bussone, G. ; Silberstein, S. D. ; Mathew, N. ; Ascher, S. ; Morein, J. ; Hulihan, J. F. ; Biondi, D. M. ; Greenberg, S. J. / Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. In: Cephalalgia. 2009 ; Vol. 29, No. 10. pp. 1021-1027.
@article{a4ded4e0a4db4ce8a3e82684a12e83ef,
title = "Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse",
abstract = "Chronic migraine has been linked to the excessive use of acute headache medications. Medication overuse (MO) is commonly considered the most significant risk factor for the progression of migraine from an episodic to a chronic condition. Managing MO is a challenge. Discontinuation of the acute medication can result in withdrawal headache, nausea, vomiting and sleep disturbances. This review summarizes the results from two similarly designed, randomized, placebo-controlled, multicentre studies of chronic migraine conducted in the USA and European Union. Both studies demonstrate the efficacy and safety of the migraine preventive medication, topiramate, for the treatment of chronic migraine in patient populations both with and without MO. These studies may have important implications for the future of chronic migraine management, suggesting that detoxification prior to initiating prophylactic therapy may not be required in all patients if MO is present.",
keywords = "Chronic migraine, Medication overuse, Topiramate",
author = "Diener, {H. C.} and Dodick, {David William} and Goadsby, {P. J.} and Bigal, {M. E.} and G. Bussone and Silberstein, {S. D.} and N. Mathew and S. Ascher and J. Morein and Hulihan, {J. F.} and Biondi, {D. M.} and Greenberg, {S. J.}",
year = "2009",
month = "10",
doi = "10.1111/j.1468-2982.2009.01859.x",
language = "English (US)",
volume = "29",
pages = "1021--1027",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "10",

}

TY - JOUR

T1 - Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse

AU - Diener, H. C.

AU - Dodick, David William

AU - Goadsby, P. J.

AU - Bigal, M. E.

AU - Bussone, G.

AU - Silberstein, S. D.

AU - Mathew, N.

AU - Ascher, S.

AU - Morein, J.

AU - Hulihan, J. F.

AU - Biondi, D. M.

AU - Greenberg, S. J.

PY - 2009/10

Y1 - 2009/10

N2 - Chronic migraine has been linked to the excessive use of acute headache medications. Medication overuse (MO) is commonly considered the most significant risk factor for the progression of migraine from an episodic to a chronic condition. Managing MO is a challenge. Discontinuation of the acute medication can result in withdrawal headache, nausea, vomiting and sleep disturbances. This review summarizes the results from two similarly designed, randomized, placebo-controlled, multicentre studies of chronic migraine conducted in the USA and European Union. Both studies demonstrate the efficacy and safety of the migraine preventive medication, topiramate, for the treatment of chronic migraine in patient populations both with and without MO. These studies may have important implications for the future of chronic migraine management, suggesting that detoxification prior to initiating prophylactic therapy may not be required in all patients if MO is present.

AB - Chronic migraine has been linked to the excessive use of acute headache medications. Medication overuse (MO) is commonly considered the most significant risk factor for the progression of migraine from an episodic to a chronic condition. Managing MO is a challenge. Discontinuation of the acute medication can result in withdrawal headache, nausea, vomiting and sleep disturbances. This review summarizes the results from two similarly designed, randomized, placebo-controlled, multicentre studies of chronic migraine conducted in the USA and European Union. Both studies demonstrate the efficacy and safety of the migraine preventive medication, topiramate, for the treatment of chronic migraine in patient populations both with and without MO. These studies may have important implications for the future of chronic migraine management, suggesting that detoxification prior to initiating prophylactic therapy may not be required in all patients if MO is present.

KW - Chronic migraine

KW - Medication overuse

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=69949145993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949145993&partnerID=8YFLogxK

U2 - 10.1111/j.1468-2982.2009.01859.x

DO - 10.1111/j.1468-2982.2009.01859.x

M3 - Article

C2 - 19735529

AN - SCOPUS:69949145993

VL - 29

SP - 1021

EP - 1027

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 10

ER -